{"symbol":"PFE","fiscalQuarter":"Q2-2026","reportDate":"2026-07-29","reportTime":"BMO","status":"upcoming","company":{"name":"Pfizer Inc.","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/PFE/earnings/Q2-2026","preBrief":{"companySnapshot":"Pfizer Inc. is a leading pharmaceutical company known for developing and producing medications and vaccines. With a market cap of $148 billion, it plays a crucial role in the healthcare sector, especially following its prominent role in COVID-19 vaccine development.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and helps investors gauge the company's financial health.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth reflects the company's ability to expand its market presence and sales, which is critical for long-term success.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1 2026, Pfizer reported an EPS of $0.75, exceeding expectations by 5.63%. The stock reacted positively, gaining 0.57% the following day.","promises":["Continue focusing on innovative treatments.","Expand vaccine distribution efforts.","Enhance research and development capabilities."]},"wallStreetExpectations":{"summary":"Investors are cautiously optimistic ahead of the earnings report, given Pfizer's strong track record of beating EPS estimates.","bullCase":"If Pfizer continues its trend of exceeding EPS expectations, it could signal robust demand for its products and lead to a significant stock price increase.","bearCase":"Concerns about declining vaccine sales and potential regulatory challenges could weigh on the stock if earnings do not meet expectations."},"optionsSignal":{"impliedMove":"9.1%","context":"The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+5.63%","reaction":"+0.57%"},{"quarter":"Q4-2025","epsSurprise":"+16.81%","reaction":"-3.34%"},{"quarter":"Q3-2025","epsSurprise":"+32.22%","reaction":"-1.46%"},{"quarter":"Q2-2025","epsSurprise":"+36.36%","reaction":"+5.18%"},{"quarter":"Q1-2025","epsSurprise":"+43.75%","reaction":"+3.21%"}],"pivotalQuestions":[{"question":"What will the EPS be for Q2-2026?","whyItMatters":"EPS is a critical measure of profitability, and any significant deviation from expectations could impact investor sentiment."},{"question":"How are vaccine sales trending compared to previous quarters?","whyItMatters":"Given the reliance on vaccine revenue, understanding sales trends will be crucial for assessing future growth potential."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $0.80 or higher would confirm strong operational performance and investor confidence.","bearTrigger":"An EPS below $0.70 could raise concerns about declining sales and profitability.","context":"This quarter's performance will hinge on Pfizer's ability to maintain its earnings momentum amid changing market dynamics."},"scenarioPlaybook":{"beatAndRaise":"If Pfizer beats expectations, history suggests a potential stock increase of around 0.46%, confirming strong demand for its products.","inLineCautious":"If results are in line with expectations, the stock may experience muted movement as investors await further guidance.","miss":"A miss could lead to a decline in stock price, with historical patterns suggesting a potential drop around 0.46%."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The market may be underestimating Pfizer's ability to sustain its growth trajectory, especially in non-vaccine segments.","supportingPoints":["Pfizer has consistently beaten EPS estimates, indicating strong operational execution.","The options market is pricing in a larger move than historical averages suggest, indicating potential for a surprise.","Recent insider trading activity shows confidence in the company's future prospects."],"riskToConsensus":"If vaccine sales decline more than expected, it could undermine the overall growth narrative."},"whatToListenFor":["Updates on new product launches and their market reception.","Details on vaccine sales trends and future expectations.","Any changes to guidance or strategic priorities.","Insights into R&D pipeline developments.","Management's outlook on market conditions and competition."],"metaDescription":"Pfizer (PFE) reports Q2 2026 earnings July 29. Analysts expect strong EPS performance amid evolving market conditions."}}